Meanwhile, rival eGenesis said it had received FDA approval in December for a separate three-patient kidney study. "The study will evaluate patients with kidney failure who are listed for a ...

Objectives To provide a comprehensive overview of interventions that support shared decision-making (SDM) for treatment modality decisions in advanced kidney disease (AKD ... 46–52), eight of which ...

Objective The purpose of the systematic review was to assess the effectiveness of remote patient monitoring (RPM) follow-up compared with standard care, for patients with chronic kidney disease (CKD) ...

The study reported that the addition of empagliflozin decreased cardiovascular death by 38% and all-cause mortality ... inflammation and renal fibrosis. Even in the absence of diabetes, SGLT2 ...

A Phase 3 clinical trial found that injections of the semaglutide medication once weekly reduced the risk of kidney disease worsening by 24% in people who also had diabetes. It also reduced the ...

Novo estimates that CKD affects some 37 million adults in the U.S., with that number likely to rise in the coming years. The condition is also a common complication of Type 2 diabetes, cropping up ...

With proper treatment, most people can survive an episode without long-term consequences. The kidney monitors the amount of fluid, electrolytes, and waste in the body and sends the excess materials to ...

In its early stages, kidney disease may not cause any symptoms or signs. However, as it progresses, it can cause symptoms such as itchy skin, pruritus, and a rash. Around 35.5 million adults in ...

Using the aspartate aminotransferase to platelet ratio index as an alternative score, liver fibrosis was correlated with magnified risk of intracerebral hemorrhage (HR, 3.76 [95% CI, 2.38–5.93]) and ...